Amgen reported a key lung cancer win for its T-cell engager strategy, pairing Imdelltra (tarlatamab) with AstraZeneca’s Imfinzi (durvalumab) to improve outcomes in advanced lung cancer. The development reinforces the company’s push to expand T-cell engager combinations across tumor types as regulatory review and competitive positioning intensify.